GlassScriptPhysician profile
Sudhakar V Girotra
NPI 1710184163
$7,317.16
in general payments reported to CMS, 2019-2025
7 companies · $3,668 in 2025
The $3,668 reported for 2025 was more than what 78% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,144 · 2020: $119 · 2021: $96.65 · 2022: $62.55 · 2023: $57.30 · 2024: $170 · 2025: $3,668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,308 · Food and Beverage: $587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,307.89 |
| Food and Beverage | $587.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,977.87 | 2024-2025 | Triclip, Mitraclip, Cardiomems |
| Philips North America LLC | $1,786.93 | 2025 | Intracardiac Undivided, Ice 3d |
| Edwards Lifesciences Corporation | $1,686.68 | 2019-2025 | Pascal, Sapien 3 Ultra Resilia |
| Medtronic Vascular, INC. | $1,349.86 | 2019-2020 | |
| Boston Scientific Corporation | $373.20 | 2019-2024 | Sentinel, Watchman Flx |
| Medtronic, INC. | $83.18 | 2021-2023 | Corevalve Evolut R |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $59.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sudhakar Girotra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.